Fig. 5.

Altered subcellular localization of HNF4α isoforms in HCC. a Western blot shows the expression of P1-HNF4α and P2-HNF4α in the soluble nuclear, cytoplasmic, and chromatin fractions of AML12, hepatoblastoma, and HCC lines. b Western blot showing the expression of BMAL1 in cellular compartments and whole cell lysates of mice expressing exclusively P1-HNF4α (WT) or P2-HNF4α (α7HMZ mice) (PonS = ponceau S). c Immunofluorescence of control tissue and metastasized human HCC specimens with antibodies specific to P1-HNF4α, P2-HNF4α, or to P1/P2-HNF4α. d Western blot showing P2-HNF4α and P1-HNF4α localization to the soluble nuclear compartment or the cytoplasm following overexpression of P2-HNF4α in AML12 cells. e FKPM counts from RNA-seq for Src, Myc, Fgfr1, Mmp14, and Cdh1 mRNAs in WT or αHMZ livers. f FKPM counts from RNA-seq for Ctnnbip1, Serpinf1, Axin1, and Porcn in WT or αHMZ livers. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001, (N = 3). Scale bar is 50 µm. Error bars = SEM